Financing ·
On September 11, 2026, Onconetix entered into a Grid Promissory Note with Realbotix to provide up to $5.0 million in…
ONCOOnconetix, Inc.
On September 11, 2026, Onconetix entered into a Grid Promissory Note with Realbotix to provide up to $5.0 million in loans, advancing an initial $2.5 million for general corporate purposes. The unsecured facility bears no interest until the earlier of the closing or termination of the pending acquisition defined by the February 11, 2026 Share Exchange Agreement; if terminated, interest accrues at 12% per annum. Upon successful closing, the note is automatically cancelled and discharged, reducing the required net cash at closing by $500,000 plus the outstanding principal balance. Realbotix Corp. guarantees these obligations. Onconetix operates in the biotechnology industry, focusing on oncology solutions.